🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 45 Essen 30 Hamburg 30 Leipzig 22 Dresden 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf74 AstraZeneca56 Janssen Research & Development, LLC33 Eli Lilly and Company30 Novartis Pharmaceuticals26 Clear sponsor filter
Site location
Berlin45 Essen30 Hamburg30 Leipzig22 Dresden22
All 110 locations
Target enrolment
to

Trials with a site in Hamburg

30 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Frankfurt, Hamburg, Landsberg am Lech, Leipzig, Mainz, Rheine
2026-08-07
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Berlin, Chemnitz, Hamburg, Leipzig, Schwerin
2026-08
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Berlin, Dachau, Hamburg, Karlsruhe, Leipzig, Offenbach
2026-05-06
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Bochum, Bünde, Duisburg, Hamburg, Karlsruhe, Leipzig, München, Offenbach
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Berlin, Bünde, Essen, Hamburg, Münster, Oldenburg
2025-12-15
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Cologne, Essen, Goch, Hamburg, Oldenburg, Stuhr
2025-12-01
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-15
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach
2025-09-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Bad Mergentheim, Bochum, Essen, Hamburg, Karlsburg, Leipzig, Münster, Oldenburg
2025-04-25
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Villingen-Schwenningen, Lingen, Cologne, Essen, Leipzig, Oldenburg in Holstein, Hamburg
2024-11-01
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Frankfurt, Hamburg, Heilbronn, Würzburg
2024-10-21
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
DrugsEltrekibart·Mirikizumab
Eli Lilly and Company
Phase 2
143
Augsburg, Berlin, Brandenburg an der Havel, Duisburg, Frankfurt am Main, Halle, Hamburg, Hanover
2024-10-10
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
DrugBaricitinib
Eli Lilly and Company
Phase 3
595
Bad Bentheim, Berlin, Dresden, Frankfurt am Main, Hamburg, Mainz, München, Münster
2023-02-27
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Bad Homburg, Bad Oeynhausen, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2022-10-11
Active, closed
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
DrugsIxekizumab·Adalimumab
Eli Lilly and Company
Phase 3
101
Freiburg im Breisgau, Sankt Augustin, Sendenhorst, Berlin, Bremen, Hamburg
2021-04-13
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994Neoplasms, Child, Adolescent
DrugsRamucirumab·Vinorelbine·Abemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
105
Essen, Freiburg im Breisgau, Hamburg
2020-01-22
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT04088409Uveitis
DrugsBaricitinib·Adalimumab
Eli Lilly and Company
Phase 3
30
Sankt Augustin, Berlin, Hamburg
2019-10-16
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
DrugBaricitinib
Eli Lilly and Company
Phase 3
190
Berlin, Hamburg, Heidelberg, Sankt Augustin, Tübingen
2019-04-05
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Berlin, Brandenburg, Halle, Hamburg, Hanover, Ludwigshafen
2018-07-18
Active, closed
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
NCT02747004Metastatic Breast Cancer
DrugsTamoxifen·Abemaciclib
Eli Lilly and Company
Phase 2
234
Ulm, Hamburg
2016-09-14
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Tübingen, Ulm, Erlangen, Hanover, Berlin, Hamburg
2016-05-19
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Ludwigsburg, Ulm, München, Wiesbaden, Düsseldorf, Lübeck, Hamburg
2014-11-06
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
DrugsErlotinib·Abemaciclib
Eli Lilly and Company
Phase 3
453
Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg
2014-10-03
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Ludwigsburg, Tübingen, Augsburg, München, Hamburg
2014-07-22
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Hamburg that also match the filters currently applied.

How many clinical trials are recruiting in Hamburg?

14 of the 30 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hamburg), 30 studies
PhaseStudiesRecruitingShare
Phase 322973.3%
Phase 27523.3%
Phase 1103.3%

Most active sponsors

Lead sponsors with the most studies (Hamburg)
Lead sponsorStudiesRecruiting
Eli Lilly and Company3014
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.